The Boston Biotech Survival Index: Big Fish Still Swimming, Minnows Getting Eaten

10/8/09Follow @xconomy

(Page 4 of 4)

Insulet (NASDAQ: PODD)
Cash on hand: $52.3 million
Related Xconomy coverage:
The Greater Boston Diabetes Cluster

Inverness Medical Innovations (NYSE: IMA)
Cash on hand: $425.5 million
Related Xconomy coverage:
Inverness to Raise $200M in Notes Sale

Javelin Pharmaceuticals (AMEX: JAV)
Cash on hand: $7.3 million
Related Xconomy coverage:
Javelin Pharma Stock Takes Hit

Millipore (NYSE: MIL)
Cash on hand: $146.6 million
Related Xconomy coverage:
Millipore Buys Guava

Molecular Insight Pharmaceuticals (NASDAQ: MIPI)
Cash on hand: $82.9 million
Related Xconomy coverage:
Imaging Agent for Early Detection of Heart Disease From Molecular Insight Reaches Goal

Momenta Pharmaceuticals (NASDAQ: MNTA)
Cash on hand: $72.1 million
Related Xconomy coverage:
Momenta Pharma Competitor Lodges Ethics Complaint Against FDA Boss, WSJ Reports
Momenta Gets Some Mojo as FDA Agrees to Review Application of Generic MS Drug

NxStage Medical (NASDAQ: NXTM)
Cash on hand: $24.5 million
Related Xconomy coverage:

Parexel International (NASDAQ: PRXL)
Cash on hand: $96.3 million
Related Xconomy coverage:
Parexel to Purchase Clinphone for $182M

To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button.
For $95,* you’ll get an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. Add to Cart
*Price is subject to change without notice

PerkinElmer (NYSE: PKI)
Cash on hand: $151.3 million
Related Xconomy coverage:
PerkinElmer Sacrifices Short Term Profits to Preserve R&D, Buy Technologies on the Cheap

Repligen (NASDAQ: RGEN)
Cash on hand: $62 million
Related Xconomy coverage:
Repligen BMS Settle Patent Suit

RXi Pharmaceuticals (NASDAQ: RXII)
Cash on hand: $4.4 million
Related Xconomy coverage:
RXi Announces $8.3M Offering
Oral RNAi Drug Stops Inflammation in Mice, RXi Says
RXi Eyes a Future of RNAi Drugs You Take as Oral Pills
Alnylam, RXi on Collision Course Over Intellectual Property From Massachusetts Life Sciences Initiative
RXi Takes an Untraditional Route to the Public Market, Now Working to Get Pharma to Pay the Bills

Sepracor (NASDAQ: SEPR)
Cash on hand: $707.2 million
Related Xconomy coverage:
Drugmaker Sepracor Accepts $2.6B Buyout Offer From Japan’s Dainippon

Synta Pharmaceuticals (NASDAQ:SNTA)
Cash on hand: $60.5 million
Related Xconomy coverage:
Glaxo Ends Synta Partnership
Synta Melanoma Drug Disastrously in Clinical Trial as Patients Show Higher Death Rate
Synta, Developer of New Class of Cancer Drugs, Eagerly Awaits Results From Key Trial

Thermo Fisher Scientific (NYSE: TMO)
Cash on hand: $1.43 billion
Related Xconomy coverage:
Thermo Fisher Names New CEO

Vertex Pharmaceuticals (NASDAQ: VRTX)
Cash on hand: $754.4 million
Related Xconomy coverage:
Vertex Drug Could Be Man Walking on the Moon for Cystic Fibrosis, Says Seattle Researcher Bonnie Ramsey
Vertex Acquires Virochem for $375M to Make Cocktail Treatments for Hepatitis C
Vertex Fending Off Competitors By Treating the Toughest Patients With Hepatitis C
Vertex CEO Josh Boger Retiring in May, Matthew Emmens to Fill Role
Out With the Hedge Funds, In With Blue Bloods, Vertex Transforms Investor Base Via Stock Sale

Waters (NYSE: WAT)
Cash on hand: $505.7 million

Zoll Medical (NASDAQ: ZOLL)
Cash on hand: $55.3 million
Related Xconomy coverage:
Zoll Medical to Buy Alsius for $12m

Single Page Currently on Page: 1 2 3 4 previous page

By posting a comment, you agree to our terms and conditions.